| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/23/2022 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 15k | $1.34 | $20.1k | | 06/23/2022 |
| 06/02/2022 | Entrada Therapeutics, Inc. | TRDA | Grant | Stock Option (Right to Buy) | 11.9k | $6.06 | $72.2k | | 06/02/2022 |
| 10/28/2021 | Entrada Therapeutics, Inc. | TRDA | Grant | Stock Option (Right to Buy) | 23.6k | $20.00 | $471k | | 10/28/2021 |
| 06/17/2021 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 15k | $26.58 | $398.7k | | 06/17/2021 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-2 Preferred Stock | 283.6k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-1 Preferred Stock | 662.8k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series A Preferred Stock | 2.1M | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 283.6k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 662.8k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 2.1M | $0.00 | $0 | See footnote | 10/20/2020 |
| 06/22/2020 | Tempest Therapeutics, Inc. | OVAS | Grant | Stock Option (right to buy) | 12k | $2.40 | $28.8k | | 06/22/2020 |
| 06/20/2019 | Tempest Therapeutics, Inc. | OVAS | Grant | Stock Option (right to buy) | 12k | $11.59 | $139.1k | | 06/20/2019 |
| 01/15/2019 | Tempest Therapeutics, Inc. | OVAS | Grant | Stock Option (right to buy) | 6k | $8.80 | $52.8k | | 01/15/2019 |
| 02/10/2016 | AveXis, Inc. | AVXS | Grant | Stock Option (Right to Buy) | 8.4k | $20.00 | $167.7k | | 02/10/2016 |
| 02/10/2016 | AveXis, Inc. | AVXS | Grant | Stock Option (Right to Buy) | 18.1k | $20.00 | $362.2k | | 02/10/2016 |